Search
Arcus Biosciences Inc
RCUSAdd to Watchlist
30.850USD
-0.230-0.74%
Close 06/30, 16:00（ET）Quotes delayed by 15 min
3.88BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-30The current earnings forecast score of Arcus Biosciences Inc is 8.00, ranking 165 out of 387 in the Biotechnology & Medical Research industry. The average price target is 32.00, with a high of 56.00 and a low of 16.00.
Analyst Rating
Based on
13
analysts
Buy
Current Rating
35.833
Target Price
+15.29%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
561
Total
5
Median
6
Average
Company name
Ratings
Analysts
Arcus Biosciences Inc
RCUS
13
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Arcus Biosciences Inc's expected revenue for the next quarter?
Arcus Biosciences Inc's expected revenue is 23.31M.
What is Arcus Biosciences Inc's price target?
Analysts forecast that Arcus Biosciences Inc's price target is USD 32.00, with the highest forecast at USD 56.00 and the lowest forecast at USD 16.00.
How have Arcus Biosciences IncRCUS's recent earnings per share performed?
The market expectation was USD -1.02, while Arcus Biosciences IncRCUS's earnings per share (EPS) for the previous quarter was USD -0.89. EPS for the next quarter is expected at USD -0.92.
What is the analyst rating for Arcus Biosciences Inc?
Based on the ratings of Arcus Biosciences Inc's stock from 13 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.